Charles River Laboratories International (NYSE:CRL – Get Free Report) was downgraded by investment analysts at William Blair from an “outperform” rating to a “market perform” rating in a note issued to investors on Wednesday, MarketBeat Ratings reports. William Blair also issued estimates for Charles River Laboratories International’s FY2025 earnings at $9.40 EPS.
Other equities research analysts have also issued reports about the company. Evercore ISI increased their price target on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. UBS Group restated a “neutral” rating and issued a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. StockNews.com downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. TD Cowen boosted their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. Finally, Citigroup cut shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and decreased their price target for the company from $215.00 to $175.00 in a research note on Tuesday, October 1st. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $204.38.
Get Our Latest Stock Report on CRL
Charles River Laboratories International Stock Performance
Charles River Laboratories International (NYSE:CRL – Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period last year, the firm earned $2.72 EPS. Sell-side analysts forecast that Charles River Laboratories International will post 10.18 EPS for the current year.
Insider Activity at Charles River Laboratories International
In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares in the company, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.30% of the stock is owned by company insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Forsta AP Fonden raised its holdings in Charles River Laboratories International by 6.6% in the 4th quarter. Forsta AP Fonden now owns 11,300 shares of the medical research company’s stock valued at $2,086,000 after buying an additional 700 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its stake in shares of Charles River Laboratories International by 3.0% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 4,354 shares of the medical research company’s stock worth $804,000 after purchasing an additional 126 shares during the last quarter. KBC Group NV lifted its stake in Charles River Laboratories International by 0.9% during the 4th quarter. KBC Group NV now owns 85,362 shares of the medical research company’s stock valued at $15,758,000 after acquiring an additional 796 shares in the last quarter. Blue Trust Inc. lifted its position in shares of Charles River Laboratories International by 7.8% during the fourth quarter. Blue Trust Inc. now owns 2,023 shares of the medical research company’s stock valued at $398,000 after purchasing an additional 146 shares in the last quarter. Finally, Flagship Harbor Advisors LLC purchased a new position in Charles River Laboratories International during the fourth quarter worth about $237,000. 98.91% of the stock is owned by institutional investors and hedge funds.
Charles River Laboratories International Company Profile
Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
Featured Articles
- Five stocks we like better than Charles River Laboratories International
- What does consumer price index measure?
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- The Significance of Brokerage Rankings in Stock Selection
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- 3 Healthcare Dividend Stocks to Buy
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.